Tirzepatide has emerged as a groundbreaking medication for type 2 diabetes, offering promising outcomes. However, the expense of this innovative drug and its access have become key issues for patients and healthcare practitioners. While tirzepatide has been authorized by regulatory agencies, its costly nature presents a significant obstacle to man